Entrada Therapeutics (TRDA) Stock Price, News & Analysis

Company Overview

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $5.87 to $6.27
• 50-Day Range: $5.02 to $7.57
• 52-Week Range: $4.93 to $21.79
• Volume: 198,835 shs
• Average Volume: 279,909 shs
• Market Capitalization: $233.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.67
• Consensus Rating: Buy

Entrada Therapeutics Stock Analysis - MarketRank™

Entrada Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 447th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Entrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Entrada Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Entrada Therapeutics are expected to decrease in the coming year, from $1.12 to ($3.23) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entrada Therapeutics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entrada Therapeutics is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entrada Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.13% of the float of Entrada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entrada Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Entrada Therapeutics has recently decreased by 11.54%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entrada Therapeutics does not currently pay a dividend.

Dividend Growth

Entrada Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.13% of the float of Entrada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Entrada Therapeutics has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in Entrada Therapeutics has recently decreased by 11.54%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.90

News Sentiment

Entrada Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Entrada Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for TRDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,782,000.00 in company stock.

Percentage Held by Insiders

Only 8.11% of the stock of Entrada Therapeutics is held by insiders.

Percentage Held by Institutions

86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TRDA Stock Analysis - Frequently Asked Questions

How have TRDA shares performed this year?

Entrada Therapeutics' stock was trading at $17.29 at the beginning of the year. Since then, TRDA stock has decreased by 64.5% and is now trading at $6.14.

How were Entrada Therapeutics' earnings last quarter?

Entrada Therapeutics, Inc. (NASDAQ:TRDA) issued its quarterly earnings data on Wednesday, August, 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by $0.18. The business had revenue of $1.98 million for the quarter, compared to analysts' expectations of $8.17 million. Entrada Therapeutics had a negative net margin of 92.30% and a negative trailing twelve-month return on equity of 17.81%.

When did Entrada Therapeutics IPO?

Entrada Therapeutics (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share.

Who are Entrada Therapeutics' major shareholders?

Top institutional investors of Entrada Therapeutics include 5AM Venture Management LLC (11.33%), Geode Capital Management LLC (1.66%), Qube Research & Technologies Ltd (0.35%) and Arrowstreet Capital Limited Partnership (0.27%). Insiders that own company stock include Bioventures 2018 LP Mpm, Ventures V LP 5Am, Kush Parmar, Dipal Doshi, Natarajan Sethuraman, Nathan J Dowden, Kory James Wentworth and Peter S Kim.
View institutional ownership trends.

How do I buy shares of Entrada Therapeutics?

Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entrada Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entrada Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TRDA
• CIK: 1689375
• Web: www.entradatx.com
• Phone: 857-520-9158
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Entrada Therapeutics: $25.67
• High Price Target: $29.00
• Low Price Target: $20.00
• Potential Upside/Downside: +318.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 5.48
• P/E Growth: N/A
• Net Income: $65.63 million
• Net Margins: -92.30%
• Pretax Margin: -96.76%
• Return on Equity: -17.81%
• Return on Assets: -14.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.64
• Quick Ratio: 18.64

Sales & Book Value

• Annual Sales: $210.78 million
• Price / Sales: 1.11
• Cash Flow: $1.66 per share
• Price / Cash Flow: 3.70
• Book Value: $9.98 per share
• Price / Book: 0.62

Miscellaneous

• Outstanding Shares: 38,040,000
• Free Float: 34,952,000
• Market Cap: $233.57 million
• Optionable: Optionable
• Beta: -0.12